State Key Laboratory of Southwestern Chinese Medicine Resources, Pharmacy College, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China; Chengdu Agricultural College, Chengdu, 611130, China.
State Key Laboratory of Southwestern Chinese Medicine Resources, Pharmacy College, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China.
J Ethnopharmacol. 2022 Oct 28;297:115537. doi: 10.1016/j.jep.2022.115537. Epub 2022 Jul 14.
ETHNOPHARMACOLOGICAL RELEVANCE: Sanhuang Xiexin decoction (SXD) is a widely applicated traditional Chinese medicine (TCM) with a significant intestinal anti-inflammatory effect. AIM OF THE STUDY: To evaluate the therapeutic effect and elucidate the possible underlying mechanisms of SXD on dextran sulfate sodium (DSS)-induced ulcerative colitis (UC) in mice. METHODS: To model UC, 3% DSS was added to the drinking water for 7 days. The UC mice were grouped and treated with three doses of SXD (1.3, 2.6, and 6 g/kg) orally for 7 days. Mice body weight and disease activity index (DAI) scores were recorded daily. After treatment with SXD, the colon was removed, and the colon length and histopathological changes were recorded. Blood cells were counted and colonic inflammatory cytokines and oxidative stress indicators were examined. The key proteins in TLR4-MyD88-NF-κB signaling and the colonic barrier were determined by Western blot analysis. The restorative effect of SXD on intestinal flora was determined. RESULTS: Treatment with SXD reduced DAI scores, increased body weight, improved colon shortening, and decreased colonic damage. SXD decreased the numbers of white blood cells (WBCs), increased the numbers of red blood cells (RBCs), and inhibited the expression of inflammatory cytokines and oxidative stress indicators. In addition, SXD displayed an effective anti-inflammatory effect by inhibiting the expression levels of p-IκBα, TLR4, MyD88, and p65. Furthermore, SXD significantly restored the integrity of the colonic barrier and the abundance of beneficial flora. CONCLUSIONS: SXD significantly reduced DSS-induced colon damage when the dose was higher than 1.3 g/kg, and the middle dose group (2.6 g/kg) indicated the best effect. SXD effectively ameliorated DSS-induced UC in mice, possibly by inhibiting oxidative stress, protecting the mucosal barrier, inhibiting the TLR4-MyD88-NF-κB signaling pathway, and regulating the intestinal flora.
民族药理学相关性:三黄泻心汤(SXD)是一种广泛应用的中药,具有显著的肠道抗炎作用。
目的:评估 SXD 对葡聚糖硫酸钠(DSS)诱导的溃疡性结肠炎(UC)小鼠的治疗效果,并阐明其可能的潜在机制。
方法:通过给饮用水添加 3%的 DSS 来建立 UC 模型,共 7 天。将 UC 小鼠分组并经口给予 SXD 三个剂量(1.3、2.6 和 6g/kg),连续治疗 7 天。每天记录小鼠体重和疾病活动指数(DAI)评分。用 SXD 治疗后,取出结肠,记录结肠长度和组织病理学变化。计数血细胞,检测结肠炎症细胞因子和氧化应激指标。通过 Western blot 分析确定 TLR4-MyD88-NF-κB 信号通路和结肠屏障中的关键蛋白。确定 SXD 对肠道菌群的修复作用。
结果:SXD 治疗降低了 DAI 评分,增加了体重,改善了结肠缩短,减少了结肠损伤。SXD 减少了白细胞(WBC)的数量,增加了红细胞(RBC)的数量,并抑制了炎症细胞因子和氧化应激指标的表达。此外,SXD 通过抑制 p-IκBα、TLR4、MyD88 和 p65 的表达水平表现出有效的抗炎作用。此外,SXD 显著恢复了结肠屏障的完整性和有益菌群的丰度。
结论:SXD 在剂量高于 1.3g/kg 时可显著减轻 DSS 诱导的结肠损伤,其中中剂量组(2.6g/kg)效果最佳。SXD 可有效改善 DSS 诱导的 UC 小鼠,可能通过抑制氧化应激、保护黏膜屏障、抑制 TLR4-MyD88-NF-κB 信号通路和调节肠道菌群来实现。
J Ethnopharmacol. 2022-5-10
J Ethnopharmacol. 2023-1-10
Front Cell Infect Microbiol. 2024
Pharmaceuticals (Basel). 2023-8-29